EP4384160A4 - HETEROCYCLIC COMPOUNDS AND METHODS OF USE - Google Patents

HETEROCYCLIC COMPOUNDS AND METHODS OF USE

Info

Publication number
EP4384160A4
EP4384160A4 EP22856568.5A EP22856568A EP4384160A4 EP 4384160 A4 EP4384160 A4 EP 4384160A4 EP 22856568 A EP22856568 A EP 22856568A EP 4384160 A4 EP4384160 A4 EP 4384160A4
Authority
EP
European Patent Office
Prior art keywords
methods
heterocyclical
compounds
heterocyclical compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22856568.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4384160A1 (en
Inventor
Michael M Yamano
Yunxiao Li
Primali Navaratne
Jose Medina
Ning Chen
Liping Pettus
Rene Rahimoff
Xiaofen Li
John Stellwagen
Francesco Manoni
Kexue Li
Brian Alan Lanman
Ryan Paul Wurz
Wei Zhao
Huan Rui
Josephine Eshon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of EP4384160A1 publication Critical patent/EP4384160A1/en
Publication of EP4384160A4 publication Critical patent/EP4384160A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP22856568.5A 2021-08-10 2022-08-10 HETEROCYCLIC COMPOUNDS AND METHODS OF USE Pending EP4384160A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163231543P 2021-08-10 2021-08-10
US202163289579P 2021-12-14 2021-12-14
PCT/US2022/039971 WO2023018812A1 (en) 2021-08-10 2022-08-10 Heterocyclic compounds and methods of use

Publications (2)

Publication Number Publication Date
EP4384160A1 EP4384160A1 (en) 2024-06-19
EP4384160A4 true EP4384160A4 (en) 2025-10-29

Family

ID=85201014

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22856568.5A Pending EP4384160A4 (en) 2021-08-10 2022-08-10 HETEROCYCLIC COMPOUNDS AND METHODS OF USE

Country Status (7)

Country Link
EP (1) EP4384160A4 (https=)
JP (1) JP2024532734A (https=)
AU (1) AU2022325771A1 (https=)
CA (1) CA3228310A1 (https=)
MX (1) MX2024001893A (https=)
TW (1) TW202330529A (https=)
WO (1) WO2023018812A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195609A2 (en) 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
EP4436571A4 (en) * 2021-11-24 2025-10-15 Merck Sharp & Dohme Llc SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
CA3247639A1 (en) 2022-05-06 2023-11-09 PAQ Therapeutics Inc. CHIMERAS TARGET KRAS-G12D PROTEOLYSIS
WO2023213269A1 (en) * 2022-05-06 2023-11-09 Zai Lab (Shanghai) Co., Ltd. Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof
CR20240508A (es) 2022-05-19 2024-12-20 Genentech Inc Compuestos aza-tetracíclicos de oxazepina y usos de los mismos
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
EP4540244A1 (en) * 2022-06-15 2025-04-23 Mirati Therapeutics, Inc. Prodrugs of pan-kras inhibitors
EP4549439A1 (en) * 2022-07-01 2025-05-07 Suzhou Zelgen Biopharmaceutical Co., Ltd. Substituted pyrimidine-fused ring inhibitor, method for preparing same, and use thereof
WO2024008068A1 (en) * 2022-07-04 2024-01-11 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024012519A1 (zh) * 2022-07-13 2024-01-18 北京华森英诺生物科技有限公司 Pan-kras抑制剂
WO2024041606A1 (zh) * 2022-08-24 2024-02-29 泰励生物科技（上海）有限公司 具有抗kras突变肿瘤活性的化合物
TW202430179A (zh) 2022-11-21 2024-08-01 美商樹線生物科學公司 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CR20250420A (es) 2023-04-07 2025-11-20 Revolution Medicines Inc Inhibidores macrocíclicos de ras
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
CN121464140A (zh) 2023-04-14 2026-02-03 锐新医药公司 Ras抑制剂的结晶形式、含有其的组合物及其使用方法
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025038936A1 (en) 2023-08-17 2025-02-20 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
TW202528315A (zh) 2023-09-21 2025-07-16 美商樹線生物科學公司 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
CN121941690A (zh) 2023-10-03 2026-04-28 Paq医疗公司 Kras蛋白水解靶向嵌合体
TW202529804A (zh) 2023-10-06 2025-08-01 美商安進公司 用於癌症治療的組合療法
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202602882A (zh) * 2024-03-14 2026-01-16 美商安進公司 作為ｋｒａｓ調節劑的大環化合物及其用途
WO2025194054A1 (en) * 2024-03-14 2025-09-18 Amgen Inc. Spirocyclic compounds as modulators of kras and uses thereof
WO2025228384A1 (en) * 2024-04-30 2025-11-06 Hutchmed Limited Antibody-drug conjugates and use thereof
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022132200A1 (en) * 2020-12-15 2022-06-23 Mirati Therapeutics, Inc. Azaquinazoline pan-kras inhibitors
WO2022228568A1 (zh) * 2021-04-30 2022-11-03 劲方医药科技(上海)有限公司 吡啶或嘧啶并环类化合物，其制法与医药上的用途
WO2022248885A2 (en) * 2021-05-28 2022-12-01 Redx Pharma Plc. Compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103588792B (zh) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
EP3908283A4 (en) * 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
MX2022002465A (es) * 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022132200A1 (en) * 2020-12-15 2022-06-23 Mirati Therapeutics, Inc. Azaquinazoline pan-kras inhibitors
WO2022228568A1 (zh) * 2021-04-30 2022-11-03 劲方医药科技(上海)有限公司 吡啶或嘧啶并环类化合物，其制法与医药上的用途
WO2022248885A2 (en) * 2021-05-28 2022-12-01 Redx Pharma Plc. Compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2023018812A1 *

Also Published As

Publication number Publication date
JP2024532734A (ja) 2024-09-10
EP4384160A1 (en) 2024-06-19
TW202330529A (zh) 2023-08-01
AU2022325771A1 (en) 2024-02-15
MX2024001893A (es) 2024-02-29
CA3228310A1 (en) 2023-02-16
WO2023018812A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
EP4384160A4 (en) HETEROCYCLIC COMPOUNDS AND METHODS OF USE
EP4384159A4 (en) HETEROCYCLIC COMPOUNDS AND METHODS OF USE
EP4384177A4 (en) HETEROCYCLIC COMPOUNDS AND METHODS OF USE
EP4306529C0 (en) FGFR INHIBITORS AND THEIR METHODS OF USE
EP4413138A4 (en) COMPOUNDS AND METHODS FOR REDUCING TAU PROTEIN EXPRESSION
EP3755690A4 (en) EGFR INHIBITORS AND THEIR PROCESSES FOR USE
EP3983386A4 (en) ACSS2 INHIBITORS AND METHODS OF USE THEREOF
EP4192476A4 (en) COMPOUNDS AND METHODS FOR MODULATING SCN2A
EP3541847A4 (en) COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
EP3743060A4 (en) ANTIBACTERIAL COMPOUNDS, RELATED COMPOSITIONS AND THEIR METHODS OF USE
EP4135687A4 (en) Polycannabinoids, compounds, compositions and methods of use
EP4139296C0 (en) COMPOUNDS AND METHODS FOR MODULATING CD73 AND INDICATIONS THEREOF
EP3941909A4 (en) Pi4-kinase inhibitors and methods of using the same
EP4401764A4 (en) Anti-Siglec-6 antibodies and their methods of use
EP3983400C0 (en) QUINAZOLINYL COMPOUNDS AND METHODS OF USE
EP4396352A4 (en) COMPOUNDS AND METHODS FOR REDUCING DMPK EXPRESSION
EP4412617A4 (en) NEW PIKFYVE INHIBITORS AND THEIR METHODS OF USE
EP4472974A4 (en) HETEROCYCLIC COMPOUNDS AND METHODS OF USE
EP4291651A4 (en) COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSION
EP3781465C0 (en) LOCKING DEVICE AND ASSOCIATED METHODS OF USE
EP4490208A4 (en) POLYZWITTERIONIC COMPLEXES AND THEIR METHODS OF USE
EP4034099A4 (en) Pimobendan formulation and method of use thereof
EP4164656A4 (en) COMPOUNDS AND METHODS FOR REDUCING MSH3 EXPRESSION
EP4069369A4 (en) CYCLIC COMPOUNDS AND METHODS OF USE
EP3817693C0 (en) ORTHOPEDIC ARCH SUPPORT DEVICE AND METHOD OF USE THEREOF

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240227

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250925

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/33 20060101AFI20250919BHEP

Ipc: A61K 31/395 20060101ALI20250919BHEP

Ipc: A61K 31/519 20060101ALI20250919BHEP